Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Finding Study of Tovinontrine in HFrEF
2023-508736-62-00Phase 2Completed
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of tovinontrine in heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Cardurion Pharmaceuticals. Started Aug 2024; status: completed.
02
Drugs
tovinontrine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2023-508736-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508736-62-00.